Clinical trials: Neoplasm, Oral
Malignant PEComa (Perivascular Epithelioid Cell Tumors)
A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa
Study objectives: The primary objective is to determine the efficacy of BEZ235 on Objective Response Rate (best response on study) according to RECIST 1.1 criteria The secondary objectives are: To determine the progression free…
- Trial name
- NCT01690871
- Testing
- BEZ235
- Where
- Spain
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation
Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy
People having radiation therapy to the head and neck often develop painful mouth problems - mouth sores, dry mouth, mouth pain, trouble eating and drinking, and changes in taste.
- Conditions
- Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation, Stomatitis (Oral Mucositis), Xerostomia Due to Radiotherapy
- Trial name
- OSEM (NCT07885033)
- Testing
- ORAL CARE PRODUCT KIT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- UNCANCER LLC
Solid Tumors, Adult, Solid Tumor
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
This is a Phase 1, first-in-human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IK-930, an oral TEAD inhibitor, administered orally…
- Conditions
- Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE)
- Trial name
- NCT05228015
- Testing
- IK-930, Osimertinib
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- Ikena Oncology
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene).
- Trial name
- NCT05241834
- Testing
- LOXO-260
- Where
- 16 sites in United States, France
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer
Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer
This is a randomized, multicenter study designed to evaluate the progression free survival of the SOL group (S-1, Leucovorin, and Oxaliplatin) compared with the mFOLFOX6 group (5-FU, l-LV and Oxaliplatin) as first-line treatment…
- Trial name
- NCT00721916
- Testing
- SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin), mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)
- Where
- Japan
- Volunteers
- 107 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Melanoma
A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma
This is a prospective, open-label, non-randomized, multicenter study in adults, aged eighteen (18) or older, with newly-diagnosed or recurrent unresectable Stage III or Stage IV melanoma.
- Trial name
- NCT00272415
- Testing
- INO-1001, temozolomide
- Volunteers
- 39 people
- Sponsor
- Genentech, Inc.
Leukemia
Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects
The primary objective of this study is to estimate the major cytogenetic response (MCyR) rate to Dasatinib in subjects with CP CML, complete and overall hematologic response (CHR and OHR) rate in subjects with AD CML or Ph+ ALL…
- Trial name
- NCT00529763
- Testing
- Dasatinib
- Where
- 14 sites in China
- Volunteers
- 121 people
- Sponsor
- Bristol-Myers Squibb
Pain, Cancer
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
The objective of the study is to monitor the safety (adverse event data) of longer-term use of ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) treatment in children with pain associated with cancer, sickle cell disease, or…
- Conditions
- Pain, Cancer, Sickle Cell Anemia, Severe Burns
- Trial name
- NCT00236093
- Testing
- ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])
- Where
- 28 sites in United States, Canada and 1 more
- Sponsor
- Cephalon
Low Risk Myelodysplastic Syndromes
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
This study will evaluate orally administered RVU120, a novel small molecule Cyclin-dependent Kinase (CDK) 8/19 inhibitor, in terms of erythroid hematologic improvement (HI-E) and safety in participants with lower-risk…
- Trial name
- (MDS) (NCT06243458)
- Testing
- RVU120 (SEL120)
- Where
- 25 sites in France, Germany and 3 more
- Volunteers
- 41 people
- Sponsor
- GCP-Service International West GmbH
Solid Tumor, Adult
A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors
BY101298 is an innovative DNA-dependent protein kinases (DNA-PK) highly selective small molecule inhibitor. DNA-dependent protein kinases (DNA-PK plays a key role in the NHEJ repair pathway to repair DNA double-strand breaks…
- Trial name
- NCT06462716
- Testing
- BY101298 Capsules
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chengdu Baiyu Pharmaceutical Co., Ltd.
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β).
- Trial name
- FORTIFI-FLEX (NCT07807163)
- Testing
- Ficerafusp alfa, Pembrolizumab (KEYTRUDA®)
- Where
- 7 sites in United States
- Volunteers
- 160 people
- Sponsor
- Bicara Therapeutics
Protein Kinase Inhibitors, Antineoplastic Protocols
A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.
The purpose of this study is to assess JNJ-26483327 (a drug in development for cancer) for the safety of the drug in patients with advanced solid tumors that have not responded or are no longer responding to available therapies.
- Conditions
- Protein Kinase Inhibitors, Antineoplastic Protocols, Clinical Trial, Phase 1, Maximum Tolerated Dose
- Trial name
- NCT00676299
- Testing
- JNJ-26483327
- Volunteers
- 19 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Carcinoma, Non-Small-Cell Lung
Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
This is an open-label, multicenter, multiple-dose, Phase I-II study of CHR-2797 co-administered with erlotinib in patients with histologically or pathologically confirmed Stage IIIB (with pleural effusion), Stage IV, or recurrent…
- Trial name
- NCT00522938
- Testing
- CHR-2797 (tosedostat), erlotinib
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Chroma Therapeutics
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
This is a multicenter, open-label, single arm phase II study to evaluate the efficacy and safety of Infigratinib in patients with locally advanced or metastatic GC or GEJ patient with FGFR2 gene amplification, who have failed at…
- Trial name
- NCT06206278
- Testing
- Infigratinib
- Where
- 30 sites in China
- Volunteers
- 6 people
- Sponsor
- LianBio LLC
Cancer
Study of XL820 in Adults With Solid Tumors
The purpose of this study is to assess the safety and tolerability of XL820 when given orally to adults with advanced solid tumors.
- Trial name
- NCT00129571
- Testing
- XL820
- Where
- 2 sites in United States
- Sponsor
- Exelixis
Cancer
VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK
The purpose of this study is to determine how dosing with ketoconazole (Nizoral) or esomeprazole (Nexium) affects the pharmacokinetics of oral pazopanib.
- Trial name
- NCT01205230
- Testing
- pazopanib
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia, Prostate Cancer
Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
Dutasteride is used in the treatment of benign prostate enlargement (BPH).It inhibits conversion of testosterone (T) into the more potent dihydrotestosterone (DHT) to stop prostate (and possibly prostate cancer) growth.
- Trial name
- NCT00375765
- Testing
- Dutasteride
- Where
- 2 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Polycystic Ovary Syndrome
Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116
This study will be conducted in a single center, double-blind with 6 dose escalation groups to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of BAY1161116.
- Trial name
- NCT03119077
- Testing
- BAY1161116, Itraconazole
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer
Head and Neck Cancer
NBTXR3 and Radiation Therapy in Treating Patients With Locally Advanced SCC of the Oral Cavity or Oropharynx
RATIONALE: Cancers of the oral cavity represent 30% of head and neck carcinomas in the western world. The oropharynx is the posterior continuation of the oral cavity and connects with the nasopharynx (above) and laryngopharynx…
- Trial name
- NCT01946867
- Testing
- NBTXR3 activated by IMRT
- Where
- 20 sites in France, Hungary and 2 more
- Volunteers
- 75 people
- Sponsor
- Nanobiotix
Cancer
A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7050 given orally in patients with advanced solid tumors.
- Trial name
- NCT00869895
- Testing
- E7050
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Eisai Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.